Search clinical trials for: T-Vec

Total 4148 results

Karie D. Runcie, MD
Amgen

Active, not recruiting

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

Angiosarcoma of Skin

United States
Shenzhen Fifth People's Hospital

Recruiting

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

CAR T-Cell Therapy

China
Royal Marsden NHS Foundation Trust

Completed

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (TITAN)

Melanoma and Sarcoma

United Kingdom
University of Zurich

Completed

T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)

Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer | Cutaneous Lymphoma

Switzerland
Dan Blazer III, M.D.

Completed

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)

Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected

United States
Amgen

Completed

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Unresectable Stage IIIB-IV Malignant Melanoma

Japan
University of Louisville

Recruiting

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Cutaneous Melanoma

United States
Zhejiang University

Recruiting

Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

Hematopoietic Stem Cell Transplantation | TP53

China
Chengdu CoenBiotech Co., Ltd
Jiangsu Province Centers for Disease Control and Prevention; Changde First... and other collaborators

Recruiting

Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.

Tuberculosis

China
University of California, Davis
Amgen

Suspended

Neoadjuvant T-VEC in High Risk Early Melanoma

Melanoma

United States
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
ViaCyte
California Institute for Regenerative Medicine (CIRM); Horizon 2020 - European...

Completed

A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

Type 1 Diabetes Mellitus With Hypoglycemia

United States, Canada, Belgium
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
BioVex Limited

Completed

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Pancreatic Cancer

United States
ViaCyte

Terminated

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (VC01-103)

Type 1 Diabetes

United States
BioVex Limited
Covance

Completed

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Melanoma
Universitair Ziekenhuis Brussel

Active, not recruiting

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (myDCTV)

Melanoma

Belgium
BioVex Limited
Symbion Research International

Completed

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Melanoma

United Kingdom, United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Sarcoma | Epithelioid Sarcoma | Cutaneous Angiosarcoma

United States
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel; ClinChoice Enterprise Management (Shanghai) Limited

Recruiting

Study of SGN1 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States, China
Vanda Pharmaceuticals

Active, not recruiting

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder

France
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
GlaxoSmithKline

Completed

CV Events in Emetogenic Chemotherapy

Vomiting | Cardiovascular Event | Arterial Thromboembolic Event
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
The University of Texas Health Science Center,...
Baylor College of Medicine; Duke University; Centers for Disease Control and... and other collaborators

Completed

Texas Childhood Obesity Research Demonstration (TX CORD) Project -Primary Prevention Study (TXCORDPRIM)

Pediatric Obesity
ViaCyte

Completed

A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Canada
Vanda Pharmaceuticals

Completed

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Circadian Rhythm Sleep Disorders

United States
Cancer Institute and Hospital, Chinese Academy...

Completed

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Breast Cancer

China
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
Centre Leon Berard
Transgene

Completed

Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX)

Advanced Tumor | Metastatic Tumor

France
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel

Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China, Taiwan
SOLTI Breast Cancer Research Group
Roche Pharma AG; Amgen

Active, not recruiting

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)

Breast Cancer

Spain
Jennerex Biotherapeutics
Solving Kids' Cancer

Completed

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

Lymphoma | Neuroblastoma | Rhabdomyosarcoma | Wilm's Tumor | Ewing's Sarcoma

United States
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Vanda Pharmaceuticals

Completed

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
Vecmedical Spain, S.L.

Recruiting

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device (UNI-VEC)

Rectal Polyp | Rectal Lesion | Sessile Colonic Polyp | Rectal Polyps | Pedunculated Colorectal Polyps

Spain
Amgen

Completed

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Melanoma

United States, France, Germany
Biotronik SE & Co. KG

Completed

Eluna Family / Sentus BP Master Study

Heart Failure | Bradycardia

Denmark, Hong Kong, Austria, Germany, Belgium
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
TriHealth Inc.
TriHealth Cancer Institute; TriHealth Surgical Institute; TriHealth Ultrasound... and other collaborators

Withdrawn

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Melanoma (Skin) | Tumor Skin | BRAF Gene Mutation | Melanoma Stage IIIb-IVM1a | Metastasis Skin

United States
University of California, Berkeley
University of Nevada, Reno; World Bank; L'Office National de Nutrition, Madagascar

Recruiting

Integrating Early Stimulation and Play at Scale: "MAHAY Mikolo"

Early Childhood Development

Madagascar
Biotronik SE & Co. KG

Completed

Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy (REFORM)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Czech Republic
Lee's Pharmaceutical Limited

Recruiting

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Local Progression or Metastatic Melanoma With Failed First-line Treatment

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Malignant Chest Wall Neoplasm | Recurrent Inflammatory Breast Carcinoma | Stage IV Inflammatory Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
University of South Florida
National Cancer Institute (NCI)

Recruiting

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors (NOURISH-T+)

Cancer | Obesity, Childhood | Survivorship

United States

Search clinical trials for: T-Vec

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations